Exelixis, Inc. (NASDAQ:EXEL)
CAPS Rating:
A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.
A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.
Recs
EXEL has a large pipeline, with one fast tracked. IMHO this stock doubles by the end of January.